DOCSLIB.ORG

Oscar 2021 Formulary

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Oscar 2021 Formulary 2021 Formulary (List of Covered Drugs) Oscar 2021 Formulary What is the Oscar Formulary? A formulary is a list of covered drugs selected by Oscar in consultation with a team of health care providers, which r epresents the prescription therapies believed to be a necessary part of a quality treatment program. Oscar will generally cover the drugs listed in our formulary as long as the drug is medically necessary, the prescription is filled at an Oscar network pharmacy, and other plan rules are followed. This Formulary was updated as of 01/01/2021. The first column of the chart lists the drug name. Brand name drugs are capitalized (e.g., BYSTOLIC) and generic drugs are listed in lower-case italics (e.g., carvedilol). There are two ways to find your drug within the formulary: 01 Medical Condition 02 Alphabetical Listing The formulary begins on page 1. The If you are not sure what category to drugs in this formulary are grouped look under, you should look for your into categories depending on the type drug in the Index that begins on page of medical conditions that they are 89. The Index provides an alphabetical used to treat. For example, drugs used list of all of the drugs included in this to treat a heart condition are listed document. Both brand name drugs and under the category, Antiarrhythmics. generic drugs are listed in the Index. If you know what your drug is used for, Look in the Index and find your drug. look for the category name in the list Next to your drug, you will see the page that begins page 1. Then look under number where you can find coverage the category name for your drug. information. Turn to the page listed in the Index and find the name of your drug in the first column of the list. Learn more at hioscar.com Oscar 2021 Formulary What are generic drugs? Oscar covers both brand name drugs and generic drugs. A generic drug is approved by the FDA as having the same active ingredient as the brand name drug. Generally, generic drugs cost less than brand name drugs. Are there any restrictions on my coverage? Some covered drugs may have additional requirements or limits on coverage. These requirements and limits may include: • Prior Authorization: Oscar requires you [or your physician] to get prior authorization for certain drugs. This means that you will need to get approval from Oscar before you fill your prescriptions. If you don’t get approval, Oscar may not cover the drug. • Quantity Limits: For certain drugs, Oscar limits the amount of the drug being filled. For example Oscar may limit a drug to only 48 pills in a 1-month timeframe. These amounts will be listed in the formulary below if they are applicable to your medication. • Step Therapy: In some cases, Oscar requires you to first try certain drugs to treat your medical condition before we will cover another drug for that condition. For example, if Drug A and Drug B both treat your medical condition, Oscar may not cover Drug B unless you try Drug A first. If Drug A does not work for you, Oscar will then cover Drug B. You can find out if your drug has any additional requirements or limits by looking in the formulary that begins on page 1. What if my drug is not on the Formulary? If your drug is not included in this formulary , you should first contact Concierge and ask if your drug is covered. If you learn that Oscar does not cover your drug, you can ask Concierge for similar drugs that are covered by Oscar. Discuss these alternatives with your doctor and ask him or her to prescribe one of the alternatives that are covered by Oscar. Learn more at hioscar.com Oscar 2021 Formulary How do I request an exception to the Oscar Formulary? Your Doctor can ask Oscar to make an exception to our coverage rules. Generally, Oscar will only approve your request for an exception if the alternative drugs included on the plan’s formulary, or additional utilization restrictions would not be as effective in treating your condition and/or would cause you to have adverse medical effects. Can the Formulary change? Most changes in drug coverage happen on January 1, but during the year Oscar may add or remove drugs on the Drug List during the year, move them to different cost-sharing tiers, or add new restrictions. You can contact Concierge to find out if your drug is still covered, visit hioscar. com and log in to your plan specific account, or use the Oscar app drug search feature. Changes that can affect you this year: • New generic drugs. We may immediately remove a brand name drug on our Drug List if we are replacing it with a new generic drug that will appear on the same or lower cost sharing tier and with the same or fewer restrictions. Also, when adding the new generic drug, we may decide to keep the brand name drug on our Drug List, but immediately move it to a different cost-sharing tier or add new restrictions. If you are currently taking that brand name drug, we may not tell you in advance before we make that change, but we will later provide you with information about the specific change(s) we have made. If we make such a change, you or your prescriber can ask us to make an exception and continue to cover the brand name drug for you. You can find information in the section above entitled “How do I request an exception to the Oscar Formulary?” • Drugs removed from the market. If the Food and Drug Administration deems a drug on our formulary to be unsafe or the drug’s manufacturer removes the drug from the market, we will immediately remove the drug from our formulary and provide notice to members who take the drug. Learn more at hioscar.com Oscar 2021 Formulary For more information For more detailed information about your Oscar prescription drug coverage, please visit www.hioscar.com or call Concierge at 1-855-OSCAR-88. You can also find your plan specific information on our Oscar app available through iTunes or Google Play. Formulary Terminology The formulary that begins on page 1 provides coverage information about the drugs covered by Oscar. If you have trouble finding your drug in the list, turn to the Index that begins on page 89. The information in the Requirements/Limits column tells you if Oscar has any special requirements for coverage of your drug. Abbreviation Term Description Your Physician must get approval from Oscar to PA Prior Authorization cover this medication Some drugs have a limit of how much you can fill at QL Quantity Limits a time For some drugs you must first try certain drugs to ST Step Therapy treat your medical condition before we will cover another drug for that condition Medications that can be purchased with1 or OTC Over-the-counter without a prescription from your Physician Prior Authorization if A Prior authorization will be needed if you do not PA** Step Therapy is not meet the step therapy met 1 to be covered at the pharmacy a prescription from your doctor is required Learn more at hioscar.com EXCH_CVSC CA 4T STND eff 01/01/2021 Drug Name Drug Tier Requirements/Limits ANALGESICS - DRUGS TO TREAT PAIN AND INFLAMMATION COX-2 INHIBITORS celecoxib CAPS 50mg, 100mg, 200mg 1 GOUT - DRUGS TO TREAT GOUT allopurinol TABS 100mg, 300mg 1 colchicine TABS .6mg 1 colchicine w/ probenecid tab 0.5-500 mg 1 febuxostat TABS 40mg, 80mg 1 ST; PA** probenecid TABS 500mg 1 NON-OPIOID ANALGESICS§ butalbital-acetaminophen-caffeine cap 50- 1 QL (48 caps / 25 days) 300-40 mg butalbital-acetaminophen-caffeine cap 50- 1 QL (48 caps / 25 days) 325-40 mg butalbital-acetaminophen-caffeine tab 50- 1 QL (48 tabs / 25 days) 325-40 mg butalbital-aspirin-caffeine cap 50-325-40 1 QL (48 caps / 25 days) mg tencon (Tencon) 1 QL (48 tabs / 25 days) NSAIDS, COMBINATIONS§ diclofenac w/ misoprostol tab delayed 1 release 50-0.2 mg diclofenac w/ misoprostol tab delayed 1 release 75-0.2 mg NSAIDS§ - DRUGS TO TREAT PAIN AND INFLAMMATION diclofenac potassium TABS 50mg 1 diclofenac sodium TB24 100mg; TBEC 1 25mg, 50mg, 75mg etodolac CAPS 200mg, 300mg; TABS 1 400mg, 500mg; TB24 400mg, 500mg, 600mg fenoprofen calcium TABS 600mg 3 flurbiprofen TABS 50mg, 100mg 1 ibuprofen SUSP 100mg/5ml; TABS 1 400mg, 600mg, 800mg ketoprofen CAPS 50mg, 75mg 1 ketorolac tromethamine SOLN 15mg/ml, 1 30mg/ml ketorolac tromethamine TABS 10mg 1 QL (20 tabs / 25 days) meclofenamate sodium CAPS 50mg, 1 100mg mefenamic acid CAPS 250mg 1 meloxicam TABS 7.5mg, 15mg 1 nabumetone TABS 500mg, 750mg 1 PA - Prior Authorization QL - Quantity Limits ST - Step Therapy OTC - Over the 1 counter OAC - Oral Anti-Cancer PA** - PA Applies if Step is Not Met Drug Name Drug Tier Requirements/Limits naproxen TABS 250mg, 375mg, 500mg 1 oxaprozin TABS 600mg 1 piroxicam CAPS 10mg, 20mg 1 sulindac TABS 150mg, 200mg 1 tolmetin sodium CAPS 400mg; TABS 1 600mg OPIOID AGONIST/ANTAGONIST§ buprenorphine hcl-naloxone hcl sl film 2- 1 QL (90 units / 25 days) 0.5 mg (base equiv) buprenorphine hcl-naloxone hcl sl film 4-1 1 QL (90 units / 25 days) mg (base equiv) buprenorphine hcl-naloxone hcl sl film 8-2 1 QL (90 units / 25 days) mg (base equiv) buprenorphine hcl-naloxone hcl sl film 12-3 1 QL (60 units / 25 days) mg (base equiv) buprenorphine hcl-naloxone hcl sl tab 2- PV QL (90 tabs / 25 days); 0.5 mg (base equiv) $0 copay buprenorphine hcl-naloxone hcl sl tab 8-2 PV QL (90 tabs / 25 days); mg (base equiv) $0 copay ZUBSOLV SUB 0.7-0.18 (buprenorphine 2 QL (90 units / 25 days) hcl-naloxone hcl dihydrate) ZUBSOLV SUB 1.4-0.36 (buprenorphine 2 QL (90 units / 25 days) hcl-naloxone hcl dihydrate) ZUBSOLV SUB 2.9-0.71 (buprenorphine 2 QL (90 units / 25 days) hcl-naloxone hcl dihydrate) ZUBSOLV SUB 5.7-1.4 (buprenorphine hcl- 2 QL (90 units
Load more

Recommended publications
  • Additions and Deletions to the Drug Product List
    Prescription and Over-the-Counter Drug Product List 40TH EDITION Cumulative Supplement Number 09 : September 2020 ADDITIONS/DELETIONS FOR PRESCRIPTION DRUG PRODUCT LIST ACETAMINOPHEN; BUTALBITAL; CAFFEINE TABLET;ORAL BUTALBITAL, ACETAMINOPHEN AND CAFFEINE >A> AA STRIDES PHARMA 325MG;50MG;40MG A 203647 001 Sep 21, 2020 Sep NEWA ACETAMINOPHEN; CODEINE PHOSPHATE SOLUTION;ORAL ACETAMINOPHEN AND CODEINE PHOSPHATE >D> AA WOCKHARDT BIO AG 120MG/5ML;12MG/5ML A 087006 001 Jul 22, 1981 Sep DISC >A> @ 120MG/5ML;12MG/5ML A 087006 001 Jul 22, 1981 Sep DISC TABLET;ORAL ACETAMINOPHEN AND CODEINE PHOSPHATE >A> AA NOSTRUM LABS INC 300MG;15MG A 088627 001 Mar 06, 1985 Sep CAHN >A> AA 300MG;30MG A 088628 001 Mar 06, 1985 Sep CAHN >A> AA ! 300MG;60MG A 088629 001 Mar 06, 1985 Sep CAHN >D> AA TEVA 300MG;15MG A 088627 001 Mar 06, 1985 Sep CAHN >D> AA 300MG;30MG A 088628 001 Mar 06, 1985 Sep CAHN >D> AA ! 300MG;60MG A 088629 001 Mar 06, 1985 Sep CAHN ACETAMINOPHEN; HYDROCODONE BITARTRATE TABLET;ORAL HYDROCODONE BITARTRATE AND ACETAMINOPHEN >A> @ CEROVENE INC 325MG;5MG A 211690 001 Feb 07, 2020 Sep CAHN >A> @ 325MG;7.5MG A 211690 002 Feb 07, 2020 Sep CAHN >A> @ 325MG;10MG A 211690 003 Feb 07, 2020 Sep CAHN >D> AA VINTAGE PHARMS 300MG;5MG A 090415 001 Jan 24, 2011 Sep DISC >A> @ 300MG;5MG A 090415 001 Jan 24, 2011 Sep DISC >D> AA 300MG;7.5MG A 090415 002 Jan 24, 2011 Sep DISC >A> @ 300MG;7.5MG A 090415 002 Jan 24, 2011 Sep DISC >D> AA 300MG;10MG A 090415 003 Jan 24, 2011 Sep DISC >A> @ 300MG;10MG A 090415 003 Jan 24, 2011 Sep DISC >D> @ XIROMED 325MG;5MG A 211690
    [Show full text]
  • Comparison of the Anti-Inflammatory Effects of Cilomilast, Budesonide
    Ratcliffe and Dougall BMC Pharmacology and Toxicology 2012, 13:15 http://www.biomedcentral.com/2050-6511/13/15 RESEARCH ARTICLE Open Access Comparison of the anti-inflammatory effects of Cilomilast, Budesonide and a p38 Mitogen activated protein kinase inhibitor in COPD lung tissue macrophages Marianne Jennifer Ratcliffe1* and Iain Gordon Dougall2 Abstract Chronic Obstructive Pulmonary Disease (COPD) is a disease characterized by a largely irreversible airflow obstruction and a persistent, excessive inflammatory response. Alveolar macrophages (AMs) are increased in the lungs of COPD patients, and act as orchestrators of the inflammatory response, releasing a range of mediators to coordinate recruitment and activation of leukocytes. Attempts to treat the inflammatory component of COPD with anti-inflammatory drugs such as steroids has met with limited success. In this study, we compared the ability of the phosphodiesterase IV (PDEIV) inhibitor Cilomilast, the steroid Budesonide, and the p38 mitogen activated protein kinase inhibitor BIRB-796 to inhibit tumour necrosis factor alpha (TNFα) and interleukin 6 (IL-6) releases from AMs isolated from COPD lung transplant tissue. All studies were carried out with appropriate ethical approval and written, informed consent was obtained from each subject. Cilomilast had little effect on cytokine release from AMs. There was considerable variability in the responsiveness of AMs to Budesonide, with a subset of AMs responding poorly to Budesonide. BIRB-796 inhibited TNFα release from all AM donors, including those that responded poorly to steroids. Treatment with BIRB-796 and Budesonide together gave an additive decrease in TNFa release. These results suggest that a p38 inhibitor may provide advantages over existing anti-inflammatory treatments for COPD, either as an add-on to existing therapy, or to treat patients who respond poorly to steroids.
    [Show full text]
  • Guanidine-Containing Polyhydroxyl Macrolides: Chemistry, Biology, and Structure-Activity Relationship
    molecules Review Guanidine-Containing Polyhydroxyl Macrolides: Chemistry, Biology, and Structure-Activity Relationship Xiaoyuan Song 1, Ganjun Yuan 1,* , Peibo Li 2 and Sheng Cao 1 1 College of Bioscience and Bioengineering, Jiangxi Agricultural University, Nanchang 330045, China; [email protected] (X.S.); [email protected] (S.C.) 2 School of Life Sciences, Sun Yat-sen University, 135 Xingang Road, Guangzhou 510275, China; [email protected] * Correspondence: [email protected]; Tel.: +86-0791-83813459 Academic Editor: Jesus Simal-Gandara Received: 7 October 2019; Accepted: 29 October 2019; Published: 30 October 2019 Abstract: Antimicrobial resistance has been seriously threatening human health, and discovering new antimicrobial agents from the natural resource is still an important pathway among various strategies to prevent resistance. Guanidine-containing polyhydroxyl macrolides, containing a polyhydroxyl lactone ring and a guanidyl side chain, can be produced by many actinomycetes and have been proved to possess many bioactivities, especially broad-spectrum antibacterial and antifungal activities. To explore the potential of these compounds to be developed into new antimicrobial agents, a review on their structural diversities, spectroscopic characterizations, bioactivities, acute toxicities, antimicrobial mechanisms, and the structure-activity relationship was first performed based on the summaries and analyses of related publications from 1959 to 2019. A total of 63 guanidine-containing polyhydroxyl macrolides were reported, including
    [Show full text]
  • Mediated Pulmonary Hypertension in Neonatal Rats: a Role for Products of Lipid Peroxidation
    0031-3998/00/4803-0289 PEDIATRIC RESEARCH Vol. 48, No. 3, 2000 Copyright © 2000 International Pediatric Research Foundation, Inc. Printed in U.S.A. Endothelin-1 and O2-Mediated Pulmonary Hypertension in Neonatal Rats: A Role for Products of Lipid Peroxidation ROBERT P. JANKOV, XIAOPING LUO, JUDY CABACUNGAN, ROSETTA BELCASTRO, HELENA FRNDOVA, STEPHEN J. LYE, AND A. KEITH TANSWELL Medical Research Council Group in Lung Development and Lung Biology Programme [R.P.J., X.L., J.C., R.B., H.F., A.K.T.], Hospital for Sick Children Research Institute, the MRC Group in Developmental and Fetal Health, Samuel Lunenfeld Research Institute, Mt. Sinai Hospital [S.J.L.], and the Departments of Obstetrics and Gynaecology [S.J.L.], Paediatrics [A.K.T.] and Physiology [A.K.T., S.J.L.], University of Toronto, Toronto, Ontario, M5S 1A8 Canada. ABSTRACT We hypothesized that reactive O2 species, or their interme- lung cell cultures. We conclude that reactive O2 species, or their diary products, generated during exposure to elevated O2 lead to bioactive intermediaries, are causative in O2-mediated pulmo- pathologic endothelin-1 expression in the newborn lung. Endo- nary hypertension and endothelin-1 up-regulation. It is likely that thelin-1 expression and 8-isoprostane content (an in vivo marker the bioactive lipid peroxidation product, 8-isoprostane, plays a of lipid peroxidation) were examined and found to be elevated key role in pathologic endothelin-1 expression and pulmonary (p Ͻ 0.05) in the lungs of newborn rats with abnormal lung hypertension during oxidant stress. (Pediatr Res 48: 289–298, morphology and pulmonary hypertension, as assessed by right 2000) ventricular hypertrophy, after a 14-d exposure to 60% O2.
    [Show full text]
  • Basic Concepts in Medicinal Chemistry, 2Nd Edition
    APP ANSWERS TO CHAPTER QUESTIONS CHAPTER 2 STRUCTURE ANALYSIS CHECKPOINT Checkpoint Drug 1: Venetoclax 1. Answers provided in table below. Functional Group Name Contribution to Water and/or Lipid Solubility A Halogen (chlorine atom) Lipid Solubility B Alicyclic ring, alkyl ring, cycloalkane Lipid Solubility C Tertiary amine (piperazine) Water Solubility D Heterocyclic ring system (pyrrolopyridine) Hydrocarbons: Lipid Solubility Nitrogen atoms: Water Solubility E Aromatic ring; phenyl ring; aromatic hydrocarbon Lipid Solubility F Sulfonamide Water Solubility G Secondary aromatic amine/aniline Water Solubility H Ether Hydrocarbons: Lipid Solubility Oxygen atom: Water Solubility 2. The sulfonamide and tertiary amine will be primarily ionized in most physiological environments and can participate in ion-dipole interactions (as the ion) with water. In the event that they are unionized, they could participate in hydrogen bonding interactions with water. The nitrogen atoms of the heterocyclic ring system, as well as the secondary aromatic amine, and the oxygen atom of the ether will not be appreciably ionized, but can participate in hydrogen bonding interactions with water. Thus, all of these functional groups contribute to the water solubility of venetoclax. The halogen as well as the hydrocarbon chains and rings are not able to ionize or form hydrogen bonds with water and thus contribute to the lipid solubility of venetoclax. 477 Unauthenticated | Downloaded 09/26/21 09:50 PM UTC 478 BASIC CONCEPTS IN MEDICINAL CHEMISTRY 3. Answers provided in table below. Electron Donating or Withdrawing Resonance or Induction A Electron Withdrawing Induction B Both Donates electrons into the aromatic ring through resonance. Withdraws electrons from adjacent methylene groups through induction.
    [Show full text]
  • Stems for Nonproprietary Drug Names
    USAN STEM LIST STEM DEFINITION EXAMPLES -abine (see -arabine, -citabine) -ac anti-inflammatory agents (acetic acid derivatives) bromfenac dexpemedolac -acetam (see -racetam) -adol or analgesics (mixed opiate receptor agonists/ tazadolene -adol- antagonists) spiradolene levonantradol -adox antibacterials (quinoline dioxide derivatives) carbadox -afenone antiarrhythmics (propafenone derivatives) alprafenone diprafenonex -afil PDE5 inhibitors tadalafil -aj- antiarrhythmics (ajmaline derivatives) lorajmine -aldrate antacid aluminum salts magaldrate -algron alpha1 - and alpha2 - adrenoreceptor agonists dabuzalgron -alol combined alpha and beta blockers labetalol medroxalol -amidis antimyloidotics tafamidis -amivir (see -vir) -ampa ionotropic non-NMDA glutamate receptors (AMPA and/or KA receptors) subgroup: -ampanel antagonists becampanel -ampator modulators forampator -anib angiogenesis inhibitors pegaptanib cediranib 1 subgroup: -siranib siRNA bevasiranib -andr- androgens nandrolone -anserin serotonin 5-HT2 receptor antagonists altanserin tropanserin adatanserin -antel anthelmintics (undefined group) carbantel subgroup: -quantel 2-deoxoparaherquamide A derivatives derquantel -antrone antineoplastics; anthraquinone derivatives pixantrone -apsel P-selectin antagonists torapsel -arabine antineoplastics (arabinofuranosyl derivatives) fazarabine fludarabine aril-, -aril, -aril- antiviral (arildone derivatives) pleconaril arildone fosarilate -arit antirheumatics (lobenzarit type) lobenzarit clobuzarit -arol anticoagulants (dicumarol type) dicumarol
    [Show full text]
  • Guadinomines, Type III Secretion System Inhibitors, Produced by Streptomyces Sp
    J. Antibiot. 61(4): 222–229, 2008 THE JOURNAL OF ORIGINAL ARTICLE ANTIBIOTICS Guadinomines, Type III Secretion System Inhibitors, Produced by Streptomyces sp. K01-0509 I. Taxonomy, Fermentation, Isolation and Biological Properties Masato Iwatsuki, Ryuji Uchida, Hitomi Yoshijima, Hideaki Ui, Kazuro Shiomi, Atsuko Matsumoto, Yoko Takahashi, Akio Abe, Hiroshi Tomoda, Satoshi O¯ mura Dedicated to the late Prof. Shigeo Iwasaki Received: January 22, 2008 / Accepted: April 4, 2008 © Japan Antibiotics Research Association Abstract Enteropathogenic Escherichia coli (EPEC) Chlamydia spp. [4]. These bacteria use TTSS to deliver expressing the Type III secretion system (TTSS) induced effector proteins into the cytosol of the eukaryotic target hemolysis of sheep blood cells. Using this assay, six cell and depend on their respective TTSS to invade the structurally related compounds designated as guadinomines host, resist phagocytosis, grow in deep tissues, and cause were isolated as inhibitors of TTSS-induced hemolysis by disease [5]. Recent studies have revealed that TTSS is not ion exchange column chromatography and HPLC from the essential for the survival of bacteria and is not found in culture broth of Streptomyces sp. K01-0509. Guadinomines non-pathogenic Gram-negative bacteria except for some A and B showed potent inhibition with IC50 values of 0.02 kinds of symbiotic bacteria. and 0.007 mg/ml, respectively, guadinomine D showed Based on the new concept of “anti-infective drugs” ¯ moderate activity (IC50: 8.5 mg/ml), while guadinomines C1 developed by Omura [6], we have focused on TTSS as a and C2 and guadinomic acid had no activity. new target for anti-infective drugs.
    [Show full text]
  • Bioisosteric Replacement As a Tool in Anti-HIV Drug Design
    pharmaceuticals Review Bioisosteric Replacement as a Tool in Anti-HIV Drug Design Alexej Dick and Simon Cocklin * Department of Biochemistry & Molecular Biology, Drexel University College of Medicine, Rooms 10307, 10309, and 10315, 245 North 15th Street, Philadelphia, PA 19102, USA; [email protected] * Correspondence: [email protected]; Tel.: +215-762-7234 or +215-762-4979 Received: 3 February 2020; Accepted: 26 February 2020; Published: 28 February 2020 Abstract: Bioisosteric replacement is a powerful tool for modulating the drug-like properties, toxicity, and chemical space of experimental therapeutics. In this review, we focus on selected cases where bioisosteric replacement and scaffold hopping have been used in the development of new anti-HIV-1 therapeutics. Moreover, we cover field-based, computational methodologies for bioisosteric replacement, using studies from our group as an example. It is our hope that this review will serve to highlight the utility and potential of bioisosteric replacement in the continuing search for new and improved anti-HIV drugs. Keywords: bioisosteres; HIV-1; antiviral; computer-aided drug design; envelope; reverse transcriptase; protease; integrase; tat; Vif 1. Introduction The design and development of a lead compound into a drug is a laborious and often costly process, with most candidates failing due to metabolism and pharmacokinetics issues rather than potency. Bioisosteric replacement is a strategy used by medicinal chemists to address these limitations while still retaining the potency/efficacy of the initial lead compound. The use of bioisosteres and the introduction of structural changes to the lead compound allows the chemist to alter the compound’s size, shape, electronic distribution, polarizability, dipole, polarity, lipophilicity, and pKa, while still retaining potent target engagement.
    [Show full text]
  • 1 Identification of a Small Molecule Inhibitor of the Aminoglycoside 6'-N
    bioRxiv preprint doi: https://doi.org/10.1101/198176; this version posted October 4, 2017. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. 1 Identification of a Small Molecule Inhibitor of the Aminoglycoside 6'-N- 2 Acetyltransferase Type Ib [AAC(6')-Ib] Using Mixture-Based Combinatorial 3 Libraries 4 5 Tung Tran,1* Kevin Chiem,1* Saumya Jani,1 Brock A. Arivett, 2,3 David Lin,1 Rupali 6 Lad,1 Verónica Jimenez,1 Mary B. Farone, 2 Ginamarie Debevec,4 Radleigh 7 Santos,4 Marc Giulianotti,4 Clemencia Pinilla,5 and Marcelo E. Tolmasky1# 8 9 1Center for Applied Biotechnology Studies, Department of Biological Science, 10 College of Natural Sciences and Mathematics, California State University 11 Fullerton, Fullerton, CA, Departments of 2Biology and 3Chemistry, Middle 12 Tennessee State University, Murfreesboro, TN, 4Torrey Pines Institute for 13 Molecular Studies, Port St. Lucie, FL, and 5Torrey Pines Institute for Molecular 14 Studies, San Diego, CA. 15 16 Word count: 3,879 17 Running Head: Inhibition of AAC(6’)-Ib 18 19 Corresponding Author: Marcelo E. Tolmasky, Professor 20 Mailing address: Department of Biological Science, CNSM, CSUF, PO Box 6850, 21 Fullerton, CA 92831-6850, US. Email: [email protected] 22 23 Co-corresponding Author: Clemencia Pinilla 24 Mailing address: 3550 General Atomics Court, 2-129, San Diego CA 92121-1122, US. 25 Email: [email protected], for or questions related to combinatorial libraries 26 27 *Tung Tran and Kevin Chiem contributed equally to this article 1 bioRxiv preprint doi: https://doi.org/10.1101/198176; this version posted October 4, 2017.
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2016/0263257 A1 Elmaleh Et Al
    US 20160263257A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2016/0263257 A1 Elmaleh et al. (43) Pub. Date: Sep. 15, 2016 (54) CROMOLYN DERVATIVES AND RELATED (52) U.S. Cl. METHODS OF IMAGING AND TREATMENT CPC ......... A61K 51/0421 (2013.01); A61K 9/4808 (2013.01); A61K 9/0075 (2013.01); A61 K (71) Applicants: David R. ELMALEH, Newton, MA 9/0053 (2013.01); A61K 31/192 (2013.01); (US); Timothy SHOUP, Waltham, MA A61K 31/352 (2013.01); A61K 9/0019 (US) (2013.01) (57) ABSTRACT (72) Inventors: David R. Elmaleh, Newton, MA (US); Novel cromolyn analogs useful as imaging agents for detect Timothy M. Shoup, Waltham, MA ing atherosclerotic plaques and for treating atherosclerosis (US) and Alzheimer's Disease, and methods of making the cro molyn analogs, are disclosed. The cromolyn analogs have (21) Appl. No.: 15/031,098 the general formula: (22) PCT Fed: Oct. 22, 2014 (I) (86) PCT No.: PCT/US1.4f61694 O S 371 (c)(1), (2) Date: Apr. 21, 2016 Related U.S. Application Data (II) (63) Continuation of application No. 14/059.924, filed on Oct. 22, 2013. Publication Classification COH: (51) Int. C. A6 IK 5L/04 (2006.01) wherein X is OH, C-C alkoxyl: Y and Z are independently A6 IK3I/352 (2006.01) selected from a C-C alkyl, C-C alkoxyl, halogen, mi A6 IK3I/92 (2006.01) substituted or C-C substituted amine, F, F, or H; and n A6 IK 9/48 (2006.01) is 1, 2, or 3; and wherein for structure (I), if n are both 1 and A6 IK 9/00 (2006.01) Y and Z are both H and X is OH.
    [Show full text]
  • FDA Listing of Established Pharmacologic Class Text Phrases January 2021
    FDA Listing of Established Pharmacologic Class Text Phrases January 2021 FDA EPC Text Phrase PLR regulations require that the following statement is included in the Highlights Indications and Usage heading if a drug is a member of an EPC [see 21 CFR 201.57(a)(6)]: “(Drug) is a (FDA EPC Text Phrase) indicated for Active Moiety Name [indication(s)].” For each listed active moiety, the associated FDA EPC text phrase is included in this document. For more information about how FDA determines the EPC Text Phrase, see the 2009 "Determining EPC for Use in the Highlights" guidance and 2013 "Determining EPC for Use in the Highlights" MAPP 7400.13.
    [Show full text]
  • Review of Existing Classification Efforts
    Project No. TREN-05-FP6TR-S07.61320-518404-DRUID DRUID Driving under the Influence of Drugs, Alcohol and Medicines Integrated Project 1.6. Sustainable Development, Global Change and Ecosystem 1.6.2: Sustainable Surface Transport 6th Framework Programme Deliverable 4.1.1 Review of existing classification efforts Due date of deliverable: (15.01.2008) Actual submission date: (07.02.2008) Start date of project: 15.10.2006 Duration: 48 months Organisation name of lead contractor for this deliverable: UGent Revision 1.0 Project co-funded by the European Commission within the Sixth Framework Programme (2002-2006) Dissemination Level PU Public X PP Restricted to other programme participants (including the Commission Services) RE Restricted to a group specified by the consortium (including the Commission Services) CO Confidential, only for members of the consortium (including the Commission Services) Task 4.1 : Review of existing classification efforts Authors: Kristof Pil, Elke Raes, Thomas Van den Neste, An-Sofie Goessaert, Jolien Veramme, Alain Verstraete (Ghent University, Belgium) Partners: - F. Javier Alvarez (work package leader), M. Trinidad Gómez-Talegón, Inmaculada Fierro (University of Valladolid, Spain) - Monica Colas, Juan Carlos Gonzalez-Luque (DGT, Spain) - Han de Gier, Sylvia Hummel, Sholeh Mobaser (University of Groningen, the Netherlands) - Martina Albrecht, Michael Heiβing (Bundesanstalt für Straßenwesen, Germany) - Michel Mallaret, Charles Mercier-Guyon (University of Grenoble, Centre Regional de Pharmacovigilance, France) - Vassilis Papakostopoulos, Villy Portouli, Andriani Mousadakou (Centre for Research and Technology Hellas, Greece) DRUID 6th Framework Programme Deliverable D.4.1.1. Revision 1.0 Review of Existing Classification Efforts Page 2 of 127 Introduction DRUID work package 4 focusses on the classification and labeling of medicinal drugs according to their influence on driving performance.
    [Show full text]